» Articles » PMID: 26721331

Glycomic Analysis of Gastric Carcinoma Cells Discloses Glycans As Modulators of RON Receptor Tyrosine Kinase Activation in Cancer

Abstract

Background: Terminal α2-3 and α2-6 sialylation of glycans precludes further chain elongation, leading to the biosynthesis of cancer relevant epitopes such as sialyl-Lewis X (SLe(X)). SLe(X) overexpression is associated with tumor aggressive phenotype and patients' poor prognosis.

Methods: MKN45 gastric carcinoma cells transfected with the sialyltransferase ST3GAL4 were established as a model overexpressing sialylated terminal glycans. We have evaluated at the structural level the glycome and the sialoproteome of this gastric cancer cell line applying liquid chromatography and mass spectrometry. We further validated an identified target expression by proximity ligation assay in gastric tumors.

Results: Our results showed that ST3GAL4 overexpression leads to several glycosylation alterations, including reduced O-glycan extension and decreased bisected and increased branched N-glycans. A shift from α2-6 towards α2-3 linked sialylated N-glycans was also observed. Sialoproteomic analysis further identified 47 proteins with significantly increased sialylated N-glycans. These included integrins, insulin receptor, carcinoembryonic antigens and RON receptor tyrosine kinase, which are proteins known to be key players in malignancy. Further analysis of RON confirmed its modification with SLe(X) and the concomitant activation. SLe(X) and RON co-expression was validated in gastric tumors.

Conclusion: The overexpression of ST3GAL4 interferes with the overall glycophenotype of cancer cells affecting a multitude of key proteins involved in malignancy. Aberrant glycosylation of the RON receptor was shown as an alternative mechanism of oncogenic activation.

General Significance: This study provides novel targets and points to an integrative tumor glycomic/proteomic-profiling for gastric cancer patients' stratification. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc.

Citing Articles

The role of -glycosylation in cancer.

Lin Y, Lubman D Acta Pharm Sin B. 2024; 14(3):1098-1110.

PMID: 38486989 PMC: 10935144. DOI: 10.1016/j.apsb.2023.10.014.


MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation.

Yu S, Chen C, Chen M, Liang J, Jiang K, Lou B J Exp Clin Cancer Res. 2024; 43(1):32.

PMID: 38268030 PMC: 10809607. DOI: 10.1186/s13046-024-02946-8.


Linking aberrant glycosylation of plasma glycoproteins with progression of myelodysplastic syndromes: a study based on plasmonic biosensor and lectin array.

Chrastinova L, Pastva O, Bockova M, Kovarova H, Ceznerova E, Kotlin R Sci Rep. 2023; 13(1):12816.

PMID: 37550349 PMC: 10406930. DOI: 10.1038/s41598-023-39927-4.


Advances in protein glycosylation and its role in tissue repair and regeneration.

Yue Z, Yu Y, Gao B, Wang D, Sun H, Feng Y Glycoconj J. 2023; 40(3):355-373.

PMID: 37097318 DOI: 10.1007/s10719-023-10117-8.


Reproducing extracellular matrix adverse remodelling of non-ST myocardial infarction in a large animal model.

Contessotto P, Spelat R, Ferro F, Vysockas V, Krivickiene A, Jin C Nat Commun. 2023; 14(1):995.

PMID: 36813782 PMC: 9945840. DOI: 10.1038/s41467-023-36350-1.